Print Friendly, PDF & Email

NCT/Study#

NCT03997968 /

CYT-0851-01-REFMAL-639

A Multi-Center, Open Label Phase 1/2 Study Of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

DISEASE GROUP:

Phase 1 Clinical Trials

current phase:

Phase I/II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587